Efficacy and Safety of Pemvidutide in the Treatment of Adults with Alcohol Use Disorder: Results from RECLAIM, a 24-Week Phase 2 Randomized Double-Blind Placebo-Controlled Trial
Kranzler HR, Tomah S, Simmons WK, et al. (2026). AASLD The Liver Meeting 2026 (late-breaking abstract).
Summary
A late-breaking conference abstract from AASLD The Liver Meeting 2026. It reports RECLAIM (NCT06987513), a randomised, double-blind, placebo-controlled phase 2 trial of weekly pemvidutide, a GLP-1 and glucagon receptor dual agonist, plus behavioural support in 100 adults with moderate-to-severe alcohol use disorder and a BMI over 25. Over 24 weeks, heavy drinking days fell by 4.20 a week with pemvidutide, compared with 2.75 on placebo, and 42.2% versus 17.4% had no heavy drinking days at the end. Phosphatidylethanol (PEth), a blood marker of alcohol intake, fell by 153.4 ng/mL with pemvidutide and rose by 22.0 ng/mL on placebo. The trial is sponsored by Altimmune, which presented the results on 9 November 2026. The figures are the company's report of that presentation. This is a conference abstract, not yet a peer-reviewed paper.